Long-Term Side Effects of Immunotherapy — What We Know So Far

Which Immunotherapy Side Effects Last Long-Term?

Most immune-related side effects settle once treatment ends or once they are treated. Some do not. Effects on the hormone glands — thyroid, pituitary and adrenal — are the ones most likely to persist for life. Joint pain, dry eyes and mouth, loss of skin pigment, reduced lung function after pneumonitis and plain fatigue can also linger.

The people who read this page are usually not frightened. They are puzzled, and quietly annoyed. Treatment finished months ago. The scans were reviewed. Everyone congratulated them. And yet the joints still ache in the morning, or the tiredness has never lifted, or the thyroid tablet that was started during treatment has simply never been stopped. Nobody prepared them for a side effect that outlasts the treatment.

Immunotherapy behaves differently from chemotherapy here. Chemotherapy side effects largely track the drug: they build during treatment and fade after it. Checkpoint inhibitors work by releasing a brake on the immune system, and once the immune system has been redirected against a healthy tissue, stopping the drug does not automatically reverse what has already happened. That is why a small number of effects continue long after the last infusion, and why a few are permanent.

What usually settles, and what tends to stay

Source: this pattern follows NCCN, ASCO and ESMO guidance on the management of immune-related adverse events, which consistently describe endocrine effects as the group least likely to reverse. The table describes patterns, not your case. What applies to you depends on which effects you actually developed, and that is read off your own records by your oncologist.

Which Long-Term Effects Are Permanent?

The clearly permanent ones are endocrine. If immunotherapy has damaged the thyroid, the pituitary or the adrenal glands, or triggered type 1 diabetes, the gland does not usually recover. Lifelong hormone replacement is then needed. Vitiligo is also usually permanent. Lung scarring after severe pneumonitis may not fully reverse.

It is worth separating two words that get used as though they mean the same thing. Permanent means the tissue does not go back to how it was. Serious means it threatens your health. They are not the same. A thyroid that has stopped working is permanent, and, once you are on the right dose of replacement, it is one of the least dramatic conditions in medicine.

• Thyroid damage. Often begins as a brief overactive phase during treatment and settles into a permanently underactive gland. Managed with a single daily tablet and periodic blood tests.
• Pituitary and adrenal effects. These matter more, because the body cannot cope with illness or surgery without steroid cover. Replacement is lifelong, and it comes with rules you need in writing from your own doctor.
• Type 1 diabetes. Uncommon, but it can appear suddenly and it does not reverse. It needs insulin and a diabetes team, not dietary advice from a website.
• Vitiligo and other pigment changes. Usually permanent, medically harmless, and for some people genuinely difficult to live with. Say so if it bothers you; it is not vanity.
• Lung and joint changes after a severe episode. Most people recover well. After a severe pneumonitis or a prolonged arthritis, some reduction in function or ongoing stiffness can remain.

Nothing here predicts what will happen to you, and no page can. Whether an effect in your case is settling, stable or permanent is a clinical judgement your oncologist makes on your examination and your current blood tests. Any cost figure you are quoted for lifelong replacement medicines is indicative only, as of August 2026.

How Much Is Still Unknown?

More than most pages admit. Checkpoint inhibitors have only been in wide clinical use since the mid-2010s, so the follow-up does not yet stretch far enough to answer some questions. Long-term chronic immune effects, fertility, second-cancer risk and very late immune behaviour are all still being studied.

This is the part of the topic where confident writing is a warning sign. A page that tells you exactly how many people still have joint pain ten years on, or exactly what immunotherapy does to fertility, is quoting a number that the published evidence does not yet support. The honest position, and the one every major guideline body takes, is that this is an area of active research where the data is still maturing.

The open questions, stated plainly

• How long chronic immune effects really last. Follow-up studies are still accumulating. Whether arthritis or sicca symptoms that persist at three years persist at ten is not yet settled.
• Fertility and pregnancy after immunotherapy. Genuinely uncertain. Trials excluded pregnancy, so the data comes from small series. This is a conversation to have with your oncologist and a fertility specialist, not a question with a published answer.
• Whether the risk of a second cancer changes. Not established either way. It is being followed, and no reliable long-term figure exists yet.
• Very late immune events. Effects appearing years after the last dose are reported, but how often they occur is not known with any precision.
• What long-term immune redirection means in old age. The first patients treated with modern checkpoint inhibitors are only now reaching a decade out. That answer will take another decade to arrive.

None of this is a reason to avoid follow-up. It is the reason for it. Where the long-term picture is incomplete, the response is regular clinician-directed review and a low threshold for investigating a new symptom — not a prediction, and not reassurance that has nothing behind it.

Can a Side Effect Start After Treatment Has Finished?

Yes. Because checkpoint inhibitors change how the immune system behaves rather than acting only while the drug is present, immune-related effects can begin weeks or months after the final dose. Endocrine effects in particular are often found late. Delayed presentations are recognised in NCCN, ASCO and ESMO guidance.

This is the single most useful thing to carry out of a survivorship appointment. A doctor who does not know you have had immunotherapy will investigate sudden diarrhoea, a new cough or collapse the way they investigate anyone else’s. Told about the drug and the date of your last dose, they investigate differently, and faster. Say it in the first sentence, every time, for the rest of your life.

Two practical habits close most of the gap. Keep a one-page treatment summary — diagnosis, drug name, dose interval, date of last dose, treating team’s number — on your phone and on paper. And if you take steroid replacement, carry a steroid card, because the people who need to read it are the people you have never met.

What Follow-Up Continues After Immunotherapy Ends?

Whatever your oncologist decides, and no fixed schedule from a website. Follow-up is set by your cancer, your treatment and the immune effects you actually had. It commonly combines clinical review, blood tests including thyroid and liver function, and imaging at intervals your team sets.

What follow-up is for changes once treatment ends. During treatment it answers whether the drug is working. Afterwards it is doing two jobs at once: watching the cancer, and watching for the late immune effects described above. Those are different questions, and it is reasonable to ask your team which of the two a particular test is for.

• Clinical review. The part that finds the most. Bring a written list of anything that has not settled, however minor it feels — joints, eyes, mouth, bowels, breathing, energy, mood.
• Blood tests. Commonly thyroid function, liver function, kidney function and blood counts, with cortisol or blood sugar added where relevant. Endocrine effects are frequently found here before you notice symptoms.
• Imaging. At intervals your oncologist sets. Response-assessment PET-CT, where it is needed, is coordinated at partner imaging centres rather than done in-house at CION, so those dates are booked around the clinic’s.
• Specialist input where a gland is involved. Endocrine effects are often shared with an endocrinologist, and that monitoring usually continues for life rather than stopping when oncology follow-up eases off.
• A written plan you actually hold. Ask for the schedule, who to contact between visits, and which symptoms mean same-day assessment. A follow-up plan that lives only in the hospital file is not much use at two in the morning.

Immunotherapy at CION is given as a day-care infusion, and the same team handles review afterwards. If you finished treatment elsewhere, bring the discharge summary, the drug name, the number of cycles and every blood report you have; a survivorship review is far more useful with the originals in the room. Read more about what a follow-up schedule after immunotherapy usually covers.

Living With an Effect That Did Not Go Away

A chronic effect after successful treatment is a strange kind of loss, and it is rarely acknowledged. The treatment worked. The scans are reassuring. And something has still changed for good. Naming it accurately is the first step to managing it, and to being taken seriously at the next appointment.

Two groups feel this most sharply. People on maintenance treatment, who never get the clean line between during and after that everyone else describes. And younger adults, for whom permanent means five decades of a daily tablet, questions about fertility that do not yet have answers, and a medical history to explain at every new job, every new city, every new doctor. Both deserve a straight conversation rather than encouragement.

• Write the symptom down before the appointment. Not “I am tired” but when it started, what it stops you doing, and whether it is better, worse or unchanged since the last visit. Vague reporting is the commonest reason a real effect gets missed.
• Do not assume tiredness is just recovery. It can be a thyroid, an adrenal or a blood-count problem, and each of those is testable. Assume it is recovery, and nothing gets looked for.
• Tell every doctor, forever. Dentists, surgeons, physicians in another city, doctors abroad. The drug name and the date of your last dose belong in your first sentence.
• Ask about fertility before you need the answer. The evidence is immature, so this is a discussion between you, your oncologist and a fertility specialist — and it is better had early than urgently.
• Ask for the mental-health side to be part of it. Living with a permanent change after treatment that worked is a common and legitimate thing to struggle with. It belongs on the follow-up list alongside the blood tests.

If a specific effect in your case has not gone away, the detail sits in the companion pages: chronic immune effects that do not go away covers what ongoing management looks like, and living with lifelong hormone replacement after immunotherapy is the practical guide if a gland is involved.

Where Survivorship Questions Usually Go Next

This page is the overview. The questions underneath it — what to do about an effect that has stayed, what daily life on replacement hormones is actually like, and how often you should be seen from here — each have their own page. If you want the general picture of the treatment first, start with immunotherapy at CION Cancer Clinics.

Finishing Treatment Is Not the End of Follow-Up

A survivorship review covers what to monitor, how often, and which symptoms should never be waited out at home.